Asset
Rinvecalinase Alfa
DiaMedica Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01845064 | phase1_2 | completed | 2013-04-01 | 2014-09-01 | DiaMedica Therapeutics Inc | A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients |
| NCT06875141 | — | withdrawn | 2025-05-01 | 2025-05-01 | DiaMedica Therapeutics Inc | DM199 for Pregnancy Complications |
| NCT04123613 | phase2 | completed | 2019-12-17 | 2022-03-16 | DiaMedica Therapeutics Inc | Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) |
| NCT03795389 | phase1 | completed | 2019-02-12 | 2019-07-21 | DiaMedica Therapeutics Inc | Study to Assess PK, Safety and Tolerability in Patients With DM and CKD |
FDA applications (0)
This company has no applications containing this asset.